Perampanel Helped Some Young Children With Hard-To-Treat Epilepsy

What was studied

This study looked at add-on treatment with perampanel in very young children with drug-resistant epilepsy. The children were 7 to 46 months old and were treated at one children's hospital in China between December 2020 and August 2024. All 87 children kept taking their usual seizure medicines, and perampanel was added.

It was a real-world study, not a randomized trial. There was no comparison group, and both families and doctors knew the children were getting perampanel. The researchers mainly measured how many children had at least a 50% drop in seizure frequency after 3, 6, 9, and 12 months. They also looked at seizure freedom, how many stayed on treatment, side effects, and whether some child characteristics were linked to treatment response.

What they found

About 4 to 5 out of 10 children had their seizure frequency cut by at least half during follow-up: 39.5% at 3 months, 46.9% at 6 months, 43.2% at 9 months, and 44.4% at 12 months. Response rates in some epilepsy syndromes were 50.0% for Dravet syndrome, 50.0% for Lennox-Gastaut syndrome, and 34.8% for infantile epileptic spasms syndrome. Among children with a genetic cause, 51.7% responded, including 60.0% of those with SCN1A variants.

Multivariable analysis identified perinatal brain injury as an independent predictor of favorable response, while concomitant use of three antiseizure medicines predicted poorer outcomes. Over time, fewer children stayed on perampanel: 87.4% were still taking it at 3 months and 55.2% at 12 months. Side effects were reported in 23.0% of children. The most common were sleepiness (11.5%) and irritability or aggressive behavior (9.2%). About 4.6% stopped the drug because of side effects.

Limits of the evidence

This study cannot prove that perampanel caused the improvements because it had no control group and was not randomized. Seizure patterns can change over time, and other medicines or care changes may have affected results.

It was done at a single hospital, with 87 children, so the findings may not apply to all young children with drug-resistant epilepsy. Some subgroup results, such as for specific syndromes or gene changes, may be based on small numbers. The abstract does not give full details on seizure freedom rates or outcomes beyond 12 months.

For families and caregivers

For families, this study suggests that perampanel may help some very young children whose seizures have not responded to other medicines. Side effects were reported in about 1 in 4 children, and a small proportion stopped treatment because of side effects.

Still, this is real-world evidence from a single-arm study rather than the strongest kind of proof. Families may see this as one possible add-on option to discuss with an epilepsy specialist, especially when weighing possible seizure benefit against sleepiness or behavior changes.

What to watch next

More evidence from larger comparative studies in infants and toddlers would help clarify how perampanel's benefits and side effects compare with other add-on options.

Terms in this summary

drug-resistant epilepsy

Epilepsy that does not come under good control after trying standard seizure medicines.

adjunctive therapy

A treatment added on to medicines a person is already taking.

antiseizure medications

Medicines used to prevent or reduce seizures.

responder rate

The percentage of patients whose seizure frequency drops by at least half.

treatment retention

How many patients keep taking a treatment over time.

treatment-emergent adverse events

Side effects or other unwanted problems that happen after starting a treatment.

Dravet syndrome

A severe epilepsy syndrome that usually begins in infancy.

SCN1A variants

Changes in the SCN1A gene, which are linked to some epilepsy conditions, including many cases of Dravet syndrome.